Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health outpatient coronavirus testing Covera…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Coronavirus Testing in the Outpatient Setting

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, limitations, and reimbursement rules for coronavirus testing performed in the outpatient setting for Oscar Health members; excludes work/school/state/federal surveillance testing and applies per member benefit at time of request.

    Policy Summary
    PayerOscar Health
    PolicyCoronavirus Testing in the Outpatient Setting
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionVerify member benefit and medical necessity before ordering outpatient coronavirus testing; document specimen type and timing relative to symptom onset.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MEETS CRITERIATargeted NAAT
    48 hrsAg-RDT frequency
    NOT COVEREDGenotyping (outpt)
    One/DOSOne code per DOS

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2026-06-16
    Last review
    2026-10-01Effective

    Coverage criteria for outpatient coronavirus testing

    Medically Necessary / Covered Testing

    Covered when ANY of the following are met:

    Targeted nucleic acid testing for COVID-19: Targeted nucleic acid testing (e.g., RT-PCR, rapid molecular tests) for COVID-19 meets criteria for: (a) individuals displaying signs and symptoms of possible COVID-19; OR (b) asymptomatic individuals with known exposure to COVID-19 EXCEPT when the individual had a previous COVID-19 infection within the last 90 days.

    See Note 1 for symptoms; applies to outpatient setting.

    Targeted nucleic acid testing for SARS: For individuals with signs or symptoms of SARS and travel to endemic areas or exposure to persons with SARS, targeted nucleic acid testing (e.g., RT-PCR) meets criteria.
    Targeted nucleic acid testing for MERS: For individuals with signs or symptoms of MERS and travel to endemic areas or exposure to persons with MERS, targeted nucleic acid testing (e.g., RT-PCR) meets criteria.
    Testing to support MIS-C, MIS-A, PASC: To support diagnosis of multisystem inflammatory syndrome in children (MIS-C), multisystem inflammatory syndrome in adults (MIS-A), or post-acute sequelae of SARS-CoV-2 infection (PASC), nucleic acid amplification testing and host antibody serology testing meet criteria.

    See Notes 2 and 3 for MIS definitions; send serology prior to IVIG when applicable.

    Antigen testing for symptomatic individuals: For symptomatic individuals, antigen-detecting diagnostic tests for SARS-CoV-2 (e.g., antigen rapid tests) meet criteria when performed once every 48 hours.once every 48 hours

    Not Medically Necessary / Not Covered

    Not covered / Does not meet criteria:

    Whole genome sequencing for reinfection diagnosis: Whole genome sequencing of paired specimens from distinct lineages for diagnosis of SARS-CoV-2 reinfection does not meet criteria.

    Distinct lineages as defined by Nextstrain or GISAID.

    SARS-CoV-2 genotyping: In the outpatient setting, SARS-CoV-2 genotyping does not meet criteria due to lack of evidence of clinical benefit.
    Neutralization antibody testing for SARS-CoV-2 does not meet criteria for any situation.
    Testing for endemic human coronaviruses: Testing for other endemic coronaviruses (229E, NL63, OC43, HKU1) does not meet criteria.
    Other unspecified situations for serology:

    IDSA NAAT testing criteria

    IDSA NAAT recommendations — covered/appropriate scenarios and constraints

    Symptomatic testing: Perform SARS-CoV-2 NAAT in symptomatic individuals suspected of having COVID-19 (strong recommendation).

    Specimen types include NP, AN, OP, MT, saliva or mouth gargle; choice may affect sensitivity.

    Specimen selection: Collect swabs from nasopharynx (NP), anterior nares (AN), oropharynx (OP), midturbinate (MT), or use saliva/mouth gargle; AN or OP alone acceptable if NP/combined collection not feasible.

    Compared to NP, AN or OP alone yield more false-negatives; follow FDA-labelled specimen types and LDT validations if deviating.

    Repeat testing after negative NAAT: Do not routinely repeat NAAT after a negative result; consider repeat testing 24–48 hours later for new/worsening symptoms, poor specimen collection, or timing issues.24-48 hours

    Conditional recommendation; not routine.

    Serology testing criteria and limitations

    Serology guidance (IDSA, AACC, AMA)

    Serology not for acute diagnosis: Do not use serologic testing to diagnose SARS-CoV-2 infection during the first two weeks after symptom onset; serology should not be the sole basis for diagnosis.<2 weeks

    IDSA strong recommendation.

    Use cases for serology: Serology can be used to provide evidence of prior infection (suggested at 3–5 weeks post-symptom onset), to assist MIS-C evaluation (with NAAT), for convalescent plasma donor screening, epidemiology/seroprevalence studies, and vaccine response studies.3-5 weeks

    AACC and IDSA guidance; AMA cautions against using serology to determine immune status.

    Serology limitations: Serologic tests may yield false positives, may not distinguish infection from vaccination (especially spike-targeting assays), and should not be used to determine individual protective immunity, return-to-work decisions, cohorting, PPE use, or placement of high-risk job functions.

    Genotyping and surveillance guidance

    Genotyping and genomic surveillance

    Genotyping clinical role: Clinical uses of SARS-CoV-2 genotyping are currently limited in routine outpatient care but may expand as interpretation and therapeutic implications evolve; laboratories should consider assay validation and reporting requirements before clinical use.

    IDSA/ASM consensus review notes limited current clinical applications.

    Genomic surveillance importance: Genomic surveillance (integrated sequencing with representative sampling) is essential to detect and monitor variants that affect transmissibility, severity, or public health measures.

    ECDC guidance emphasizes robust surveillance strategies.

    Asymptomatic screening recommendations

    Asymptomatic screening stance (SHEA/ASA/APSF)

    Against universal asymptomatic screening: Recommend against routine universal asymptomatic screening for SARS-CoV-2 in healthcare facilities when other infection prevention layers are in place; pre-procedure asymptomatic screening is unlikely to provide incremental benefit.

    SHEA statement supported by ASA and APSF; recommend facility-specific risk/benefit analysis.

    When admission screening may be beneficial: Admission screening may be considered during periods of increased community transmission or in settings with limited other controls (eg, behavioral health, congregate care, shared rooms).

    Local infection prevention assessment recommended.

    Covered testing indications and clinical pathways

    Guidance-driven testing indications and pathways (synthesized from cited authorities):

    Symptomatic testing: Test all people with COVID-19 symptoms as soon as possible after symptom onset; NAATs and antigen tests are acceptable for symptomatic children; repeat antigen testing at 48 hours may be reasonable after a negative antigen result.

    Sources: ECDC, AAP

    Surveillance during influenza season: Test all patients with acute respiratory symptoms and sentinel primary care specimens for both SARS-CoV-2 and influenza during influenza season to monitor incidence and trends.

    Source: ECDC

    Testing in healthcare and congregate settings: Implement intensive, periodic, and comprehensive testing of staff and residents/patients when community transmission is documented; test patients/residents upon or just prior to admission.

    Source: ECDC

    This policy applies only to outpatient testing performed for medical decision-making and is applied based on the member's benefit coverage at the time of the request. It does not address testing that is mandated for work, school, state, or federal surveillance purposes. Providers should verify member benefits and document medical necessity when ordering testing in the outpatient setting.

    Host antibody (serologic) tests detect immunoglobulins produced after SARS‑CoV‑2 infection, but they are not appropriate for diagnosing or excluding acute infection. FDA guidance and the policy state that antibody test results should not be used as the sole basis for clinical decisions about active infection because antibodies typically develop days to weeks after symptom onset and may be absent in the early phase.

    Antigen tests identify viral proteins and can be useful for point-of-care diagnosis, but they have important limitations: they may not distinguish SARS‑CoV from SARS‑CoV‑2, cannot differentiate viable from non‑viable virus, and negative results can occur when viral levels are below the test's limit of detection. Negative antigen results should be considered presumptive and confirmed with an FDA‑authorized molecular assay when clinically necessary; strict adherence to manufacturer procedure is required to avoid invalid results.

    Multiplex respiratory panels (e.g., BioFire RP2.1, QIAstat‑Dx) detect multiple pathogens from a single specimen but are not validated for use in individuals without signs or symptoms of respiratory infection. Panel results should not be the sole basis for diagnosis or treatment decisions; negative results do not exclude infection and unexpected detections may require confirmatory testing and clinical correlation.

    The World Health Organization does not recommend using saliva as the sole specimen type for routine clinical diagnostics. While saliva‑based assays exist (e.g., SalivaDirect), WHO guidance endorses nucleic acid testing as the routine confirmatory method and cautions against relying solely on saliva for routine diagnosis.

    Professional organizations and laboratory guidance advise that serologic testing should not be used to determine an individual's protective immunity, to make return‑to‑work decisions, for cohorting, or to direct PPE use or placement of high‑risk job functions. Antibody results may reflect prior infection or vaccination and do not reliably indicate current infectiousness or level of protection.

    Antibody tests are intended to indicate past infection or vaccination response and are not useful for diagnosing acute infection. They cannot determine current infectiousness or precisely time an infection, and spike‑targeting assays may not distinguish prior infection from vaccination; therefore antibody results should not be used to infer infectiousness or the timing of infection.

    SARS‑CoV‑2 genotyping, neutralization antibody testing, and testing for endemic human coronaviruses (229E, NL63, OC43, HKU1) in the outpatient setting do not meet criteria due to insufficient evidence of clinical benefit and are considered not medically necessary under this policy.

    Point‑of‑care serological tests using lateral flow immunoassays (LFIA) have demonstrated limited sensitivity in meta-analyses and available evidence does not support continued use of existing point‑of‑care serologic tests for diagnostic purposes in the outpatient setting.

    The BioFire RP2.1 panel has not been established for specimens collected from individuals without signs or symptoms of respiratory infection and has not been validated for monitoring treatment. Using this panel for asymptomatic screening or to monitor therapy is not supported by its intended use and should not be relied on for those purposes.

    IDSA guidance suggests against routine NAAT screening of asymptomatic individuals without a known exposure for hospital admission or procedures (conditional recommendation, very low certainty). Routine pre‑procedure NAAT in asymptomatic, unexposed individuals is generally not supported except in specific high‑risk situations identified by local infection control assessments.

    Procedure, specimen, and reimbursement coding

    Provider actions, documentation, and billing guidance

    Prior Authorization

    Verify member benefit and medical necessity

    Coverage is determined by the member’s benefit at the time of the request and whether the test meets medical necessity criteria; the policy itself does not guarantee reimbursement and providers must verify benefit eligibility before ordering.

    • Application of criteria is dependent upon an individual's benefit coverage at time of request (III).
    • Services must meet authorization and medical necessity guidelines; coverage does not guarantee reimbursement (Important Note).
    Note

    Consider low yield and impact of asymptomatic pre‑procedure RT‑PCR

    Routine pre‑operative RT‑PCR screening in asymptomatic patients has a low positive rate (0.41% in one study) and can cause delays and added costs; consider local testing protocols and document rationale when authorizing elective procedures.

    • Study of 7,579 pre‑procedural tests found 31 (0.41%) positives, with many procedures delayed (average delay 49 days) and high cost per positive.

    Background and evidence context

    Human coronaviruses include endemic common‑cold strains (e.g., 229E, NL63, OC43, HKU1) and the epidemic/pandemic strains SARS‑CoV, MERS‑CoV, and SARS‑CoV‑2. Diagnostic modalities discussed in this policy include nucleic acid amplification tests (RT‑PCR/NAAT), antigen detection assays, and host antibody serology. Severe COVID‑19 can lead to hospitalization, respiratory failure, and multisystem complications; testing modality selection should consider timing relative to symptom onset, specimen type, and the clinical question being asked.

    Definitions and test modality terms

    COVID-19 / SARS-CoV-2 — disease and testing modalities
    TermCOVID-19 / SARS-CoV-2
    DefinitionThe disease and causative virus responsible for the global COVID-19 pandemic; testing modalities include molecular (NAAT/RT-PCR), antigen, and host antibody (serology) assays.
    Clinical relevanceCan cause a spectrum from mild respiratory illness to severe disease (≈15% severe requiring oxygen; ≈5% critical) and multiorgan complications.
    MIS-C / MIS-A — multisystem inflammatory syndromes definitions
    TermMIS-C / MIS-A
    DefinitionMultisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A) — clinical syndromes defined by CDC/CSTE characterized by fever, systemic inflammation, multi-organ involvement, and requirement for hospitalization or severe illness.

    Policy revision and governance history

    Policy Summary
    PayerOscar Health
    PolicyCoronavirus Testing in the Outpatient Setting
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionVerify member benefit and medical necessity before ordering outpatient coronavirus testing; document specimen type and timing relative to symptom onset.
    SourceLink
    On This Page
    Coverage criteria for outpatient coronavirus testingProcedure, specimen, and reimbursement codingProvider actions, documentation, and billing guidanceBackground and evidence contextDefinitions and test modality termsPolicy revision and governance history
    Host antibody serology testing does not meet criteria in situations not specifically described as covered above.
    Asymptomatic persons with exposure: SARS-CoV-2 RNA testing is suggested in asymptomatic individuals with known or suspected exposure; test at least 5 days after exposure or immediately if symptoms develop earlier.>=5 days post-exposure unless symptomatic

    Conditional recommendation; useful for isolation decisions and for high-risk individuals.

    Asymptomatic without exposure: Suggest against routine NAAT in asymptomatic individuals without known exposure for hospital admission or procedures (conditional, very low certainty).

    May be considered during high community transmission or specific settings.

    NAAT repeat for release from isolation or pre-procedure: Suggest against routinely repeating NAAT to guide release from isolation or routinely repeating before procedures in patients with recent COVID-19 because RNA detection may not reflect infectious virus.

    Consider patient and procedure factors instead of routine repeat testing.

    AACC and AMA statements.

    MIS-C evaluation:
    Evaluate children with persistent fever (≥3 days) who are moderately to severely ill and consider laboratory screening for systemic inflammation; perform RT-PCR and serologic testing for SARS-CoV-2 as part of MIS-C workup and send serology prior to IVIG administration.

    Sources: AAP, CDC/CSTE, ACR

    Outbreak/population testing: Consider whole-population testing in areas experiencing high community transmission to identify infectious cases and interrupt transmission; targeted testing and follow-up for travelers from areas without sustained control may be considered to prevent re-introduction.

    Source: ECDC

  1. Consider documented testing protocols and cost/benefit when authorizing elective procedures.
  2. Step Therapy

    Choose and justify multiplex panel selection

    When ordering multiplex respiratory panels, select the panel appropriate to the clinical presentation and document rationale because panels detect multiple pathogens from a single nasopharyngeal specimen, can be costly, and may show preferential amplification or reduced sensitivity for certain targets.

    • Multiplex panels (e.g., BioFire RP2.1, QIAstat‑Dx, ePlex, cobas SARS‑CoV‑2 & Influenza A/B, Xpert Xpress SARS‑CoV‑2/Flu/RSV) detect and differentiate multiple pathogens from one NP specimen (Panel Testing).
    • Panels can produce false‑negatives due to preferential amplification and have limitations (e.g., BioFire RP2.1 not established for asymptomatic individuals).
    • Document clinical indication and rationale when ordering multiplex testing due to cost and potential assay limitations.
    Prior Authorization

    No prior authorization specified in this section

    This section contains no explicit prior authorization requirements or routine prior authorization codes; providers should follow benefit verification and medical necessity policies when seeking authorization.

    • No prior authorization statements are included in this section (Panel Testing).
    • Follow benefit verification and applicable authorization processes per member benefit documents.
    Prior Authorization

    No explicit prior authorization requirements stated

    No explicit prior authorization requirements are specified in these clinical and testing guidance sections; adhere to benefit verification and authorization procedures in the member’s plan when applicable.

    • Policy text states no explicit prior authorization requirements in this section (Miscellaneous Testing).
    Documentation Required

    Adhere to FDA‑labeled specimen types for NAATs

    NAATs must be used per their FDA‑authorized labeling for specimen types and collection methods; deviations require LDT validation or an FDA EUA and failure to follow label requirements can lead to inaccurate results and reimbursement denials.

    • FDA approval indicates specific collection and specimen types; failure to adhere to label requirements without LDT validation or EUA can cause inaccurate results and reimbursement denials (IDSA).
    Billing Rule

    Use listed procedure codes and document testing context

    Include appropriate procedure codes when requesting coverage: SARS‑CoV‑2 antibody (86413, 86769), nucleic acid detection (87798), and CDC/non‑CDC RT‑PCR panels (U0001, U0002); report place of service and clinical context as required.

    • Applicable CPT/HCPCS codes listed for reference include 86413, 86769, 87798, U0001, U0002 (Applicable CPT/HCPCS Procedure Codes).
    • Providers should include appropriate place of service and the clinical testing context when submitting requests or claims.
    Note

    Publication history contains no authorization/billing directives

    Evidence/publication sections document governance approval (06/16/2026) and list references but do not address prior authorization or billing actions; providers must rely on benefit and reimbursement sections for billing rules.

    • Publication History: Governance approved 06/16/2026 and reference list provided (Publication History, Evidence).
    • No prior authorization or billing actions are specified in these reference chunks.
    Billing Rule

    Bill a single procedure code; specimen collection incidental

    Only one procedure code will be reimbursed per date of service; specimen collection codes for coronavirus testing are considered incidental and will not be reimbursed separately—ensure claims reflect a single appropriate code.

    • AMA guidance: only one code per date of service will be reimbursed (V. Reimbursement).
    • Specimen collection codes are considered incidental and will not be reimbursed (V. Reimbursement).
    Step Therapy

    Prefer RT‑PCR/validated NAATs for acute infection

    For acute infection diagnosis, prefer RT‑PCR/NAATs with assays and primers validated for SARS‑CoV‑2; rapid NAATs may be acceptable in symptomatic patients per IDSA and CDC hierarchies.

    • RT‑PCR is used to diagnose acute infection when appropriate primers target SARS‑CoV‑2 (Nucleic Acid Testing).
    • CDC and IDSA guidance favor NAATs for high sensitivity; rapid NAATs may be used depending on context and validated assays (CDC, IDSA).
    Denial Risk

    Confirm negative antigen results with molecular testing when clinically necessary

    A negative antigen test in a symptomatic patient should be considered presumptive; confirm with an FDA‑authorized molecular assay (NAAT) when needed for clinical management or infection control.

    • Antigen negative results 'should be treated as presumptive and confirmed with an FDA authorized molecular assay, if necessary, for clinical management, including infection control' (Clinical Utility of Antigen Testing).
    • CDC advises that a single negative antigen test cannot rule out infection; repeat antigen tests or NAAT confirmation may be needed (CDC).
    Step Therapy

    Use pathogen‑specific molecular tests for suspected Bordetella pertussis

    For suspected Bordetella pertussis, use an FDA‑cleared, pathogen‑specific molecular test rather than a broad multiplex panel (e.g., BioFire RP2.1) because panels may have reduced sensitivity for B. pertussis.

    • BioFire and other panels have limitations and may show reduced sensitivity for certain targets such as B. pertussis; use specific FDA‑cleared molecular tests when pertussis is suspected (Clinical Utility of Panel Testing).
    Note

    Follow CDC/IDSA testing hierarchy when selecting tests

    Use CDC and IDSA testing hierarchies when selecting tests: NAATs preferred for sensitivity; antigen tests may be used with specific repeat‑testing algorithms based on exposure and symptom status.

    • CDC guidance lists NAATs as most highly recommended due to sensitivity and specificity (CDC).
    • IDSA suggests using rapid or standard NAATs in symptomatic individuals and provides conditional guidance on specimen types and repeat testing (IDSA).
    Step Therapy

    Do not routinely repeat NAAT; consider 24–48 hour repeat when indicated

    Routine repeat NAAT is not suggested after a negative initial test; consider repeat testing 24–48 hours later only for new or worsening symptoms, poor specimen collection, or timing concerns.

    • IDSA: do not routinely repeat NAAT after a negative result; consider repeat testing 24–48 hours later for new/worsening symptoms or poor specimen collection (IDSA recommendations).
    Step Therapy

    Testing approach for symptomatic children: antigen or NAAT; repeat antigen at 48 hours if negative

    For symptomatic children, either antigen tests or NAATs can be used; if an antigen test is negative in a symptomatic child, consider repeating the antigen test at 48 hours per AAP/FDA guidance or confirming with NAAT as clinically indicated.

    • AAP: NAATs and antigen tests acceptable for symptomatic children; providers may repeat antigen testing at 48 hours for a negative result (AAP).
    • CDC/IDSA: antigen testing has specific repeat algorithms and NAAT preferred for sensitivity in many settings.
    Note
    Documentation Required

    Document services and verify benefits before testing

    Providers must submit accurate documentation of services performed and verify member benefits; ensure records support medical necessity and any authorization requested.

    • Policy notes providers are responsible for submission of accurate documentation and that services must meet authorization and medical necessity guidelines (Important Note, III).
    • Application of criteria depends on individual's benefit coverage at time of request (III).
    Documentation Required

    Record specimen type and timing relative to symptoms

    When reporting NAAT results, document specimen type and timing relative to symptom onset because sensitivity varies by specimen site and timing; anterior nasal swabs may have adequate sensitivity compared with oropharyngeal specimens in some studies.

    • Document specimen type and timing relative to symptom onset; specimen choice affects sensitivity (Clinical Utility and Validity).
    • Study showed anterior nasal swabs had adequate sensitivity vs oropharyngeal swabs in one analysis (Li et al.).
    Documentation Required

    Document antigen test procedure and adherence to manufacturer instructions

    Follow manufacturer instructions and document test procedure for instrument‑dependent antigen tests (e.g., Sofia®2), including specimen type (nasal vs nasopharyngeal) and adherence to processing/timing to avoid invalid results.

    • Sofia®2 requires specific operation modes and specimen types; accurate performance per manufacturer instructions is required (Antigen Testing).
    • Failure to follow the test procedure can invalidate results; document adherence to manufacturer steps and specimen type.
    Documentation Required

    Correlate panel results clinically and arrange follow‑up testing if needed

    Combine panel results with clinical observations, patient history, and epidemiologic information; unexpected detections or inability to differentiate organisms may require follow‑up testing or sequence analysis.

    • Panel results should not be used as the sole basis for patient management; negative results must be combined with clinical observations and epidemiologic information (ePlex/BioFire guidance).
    • If differentiation (e.g., rhinovirus vs enterovirus) is required, follow‑up testing such as cell culture or sequencing may be needed.
    Documentation Required

    Document MIS‑C / MIS‑A clinical and laboratory criteria including SARS‑CoV‑2 testing

    For MIS‑C and MIS‑A evaluations, document clinical and laboratory criteria per CDC definitions and include SARS‑CoV‑2 testing (NAAT, antigen, or serology) within specified windows to support case classification.

    • CDC MIS case definitions require documentation of clinical criteria and laboratory evidence (detection of SARS‑CoV‑2 RNA, antigen, or antibodies up to 60 days prior or during hospitalization).
    • Ensure testing and clinical data are recorded to meet Confirmed, Probable, or Suspect classifications.
    Documentation Required

    Adhere to and document specimen collection and transport requirements

    Collect and transport specimens according to test‑specific instructions and approved specimen types; document collection method and transport conditions to ensure result quality and reimbursement compliance.

    • Appropriate specimen collection and transport are critical; follow test‑specific instructions including approved specimen types and methods (IDSA, ePlex/BioFire guidance).
    • Document specimen type and collection method to support interpretation and payer review.
    Documentation Required

    Send serology before IVIG for MIS‑C evaluation

    When evaluating MIS‑C, send serologic testing prior to administration of IVIG because IVIG can affect serology results and timing influences interpretation.

    • AAP: 'Serologic tests must be sent prior to administration of intravenous immunoglobulin (IVIG)' for MIS‑C evaluation.
    Note

    Cite evidence references when documenting clinical rationale

    Refer to the policy’s evidence references to support clinical decisions and coverage rationale; the publication history and reference list are provided but include no direct provider action steps beyond citation.

    • Evidence‑based references are listed (items 43–56 shown) to support clinical decisions (X. Evidence‑based Scientific References).
    • Publication history records governance approval on 06/16/2026.
    Denial Risk

    Ensure coding and billing comply with policy and AMA/CMS guidance

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed; ensure coding matches the documented clinical indication and follow AMA/CMS coding guidance.

    • Policy warns that failure to follow coding/billing guidelines or current reimbursement policies may result in claim denials or recoupment (Important Note).
    • AMA guidance: only one code per DOS reimbursed; specimen collection incidental—bill accordingly (V. Reimbursement).
    Denial Risk

    Do not rely solely on negative NAAT/RT‑PCR for management

    Do not use a negative RT‑PCR result as the sole basis for patient management; consider timing of specimen collection, specimen quality, and clinical context because false negatives can occur early in infection or with poor collection.

    • 'Negative results do not preclude SARS‑CoV‑2 infection and should not be used as the sole basis for patient management decisions' (Clinical Utility and Validity of NAAT).
    • Initial false negatives may result from improper collection or testing early in incubation period; interpret results with clinical context.
    Denial Risk

    Confirm negative antigen tests with NAAT when clinically indicated

    Treat negative antigen results as presumptive; confirm with an FDA‑authorized molecular assay when necessary for clinical management or infection control, and ensure test procedures were followed to avoid invalid results.

    • Clinical Utility: 'All negative results should be treated as presumptive and confirmed with an FDA authorized molecular assay, if necessary, for clinical management, including infection control.'
    • Failure to follow test procedure can adversely affect performance and invalidate antigen test results.
    Denial Risk

    Avoid using BioFire RP2.1 for treatment monitoring or asymptomatic screening

    Do not use the BioFire RP2.1 panel for treatment monitoring or routine asymptomatic screening; results from the panel should not be the sole basis for diagnosis or treatment decisions.

    • BioFire RP2.1 'has not been established for specimens collected from individuals without signs or symptoms of respiratory infection' and 'has not been validated for the monitoring of treatment'.
    Denial Risk

    Recognize practical and regulatory limits on whole genome sequencing

    Whole genome sequencing is limited by lack of FDA‑approved tests and practical barriers (high cost, reagent shortages, need for specialized infrastructure and trained staff); consider these limitations before ordering WGS for clinical purposes.

    • WGS 'presents practical difficulties such as high cost, shortage of available reagents, need of specialized laboratorial infrastructure and well‑trained staff' and as of May 4, 2022, there are no FDA‑approved WGS tests.
    Denial Risk

    Follow FDA label requirements for specimen collection or validate deviations

    Adhere to FDA label requirements for specimen collection and specimen types unless the laboratory has validated the test as an LDT or the method is authorized by an EUA; failure to do so can produce inaccurate results and reimbursement denials.

    • IDSA: FDA approval of NAATs indicates specific collection and specimen types; failure to adhere to label requirements without proper validation can lead to inaccurate results and reimbursement denials.
    Note

    Apply government coverage policy precedence (LCD/NCD) when conflicts exist

    If this policy conflicts with applicable government policies (LCDs/NCDs), government policy takes precedence in coverage determinations; verify applicable Medicare/Medicaid rules when relevant.

    • 'If there is a conflict between this Policy and any relevant, applicable government policy... then the government policy will be used to make the determination' (Applicable State and Federal Regulations).
    Note

    Publication history notes governance approval but no billing directives

    Publication history records governance approval on 06/16/2026; these sections do not specify any prior authorization or billing actions—use the reimbursement and coding sections for billing rules.

    • Publication History: 06/16/2026 Original Documentation; Governance Approved.
    • Reference and publication chunks contain no explicit authorization or billing directives.
    Key diagnostic featuresFever ≥38°C; evidence of systemic inflammation (e.g., elevated CRP); new onset manifestations in ≥2 organ systems (cardiac, mucocutaneous, gastrointestinal, hematologic, shock); plus evidence of SARS-CoV-2 infection or exposure within defined windows.
    RT-PCR — reverse-transcription polymerase chain reaction definition
    TermRT-PCR (reverse-transcription polymerase chain reaction)
    DefinitionA molecular NAAT that converts viral RNA to complementary DNA (cDNA) and amplifies target sequences using primers to detect acute SARS-CoV-2 infection; highly sensitive and specific but requires laboratory instrumentation.
    LimitationsMay remain positive for up to 90 days after infection and cannot be used to determine past infection timing; not ideal as rapid point-of-care without rapid NAAT formats.
    Host antibody testing (serology) — definition and intent
    TermHost antibody testing (serology)
    DefinitionAssays that detect host immunoglobulins (IgM, IgA, IgG or total antibodies) produced in response to SARS-CoV-2 infection or vaccination; used to identify prior infection, support MIS-C evaluation, donor screening, epidemiology, or vaccine-response studies—not for acute diagnosis.
    Timing and limitsAntibodies typically develop days to weeks after infection (IgG best detected after ~3–5 weeks); serology should not be used within the first 2 weeks to diagnose acute infection and cannot determine current infectiousness or reliably distinguish vaccination vs infection for spike-targeting assays.
    Variant classifications — CDC variant categories
    TermVariant classifications (CDC)
    CategoriesVariants being monitored (VBM), Variants of Interest (VOI), Variants of Concern (VOC), Variants of High Consequence (VOHC).
    Basis for categoriesClassifications reflect attributes such as transmissibility, disease severity, impact on diagnostics, therapeutics, or vaccine effectiveness; VOHC indicates clear evidence of substantially reduced effectiveness of countermeasures.
    Antibody testing — assay types and timing
    TermAntibody testing — assay types and timing
    Assay typesCommon platforms include ELISA, CLIA, FIA, and LFIA (lateral flow); neutralization assays detect functional antibodies while binding assays detect total or class-specific antibodies.
    TimingSensitivity improves over time from symptom onset; IgG and combined IgG/IgM detection is most reliable 3–5 weeks post-symptom onset; serology not recommended for acute diagnosis within first 2 weeks.
    Antigen testing — antigen assay definition and point-of-care use
    TermAntigen testing (Ag tests / Ag-RDT)
    DefinitionAssays that detect SARS-CoV-2 viral proteins (e.g., nucleocapsid or spike) in patient specimens; rapid formats (Ag-RDTs) provide quick results (15–30 minutes) and are suitable for point-of-care or self-testing when performance criteria met.
    Performance & useWHO recommends Ag-RDTs with minimum performance ≥80% sensitivity and ≥97% specificity versus NAAT, and use within 5–7 days of symptom onset; negative antigen results in symptomatic patients often require confirmatory molecular testing.
    Multiplex respiratory panels — definition and purpose
    TermMultiplex respiratory panels
    DefinitionLaboratory assays (often multiplex PCR) that detect and differentiate multiple respiratory pathogens (including SARS-CoV-2) from a single specimen to enable differential diagnosis.
    ConsiderationsUseful when multiple pathogens present with similar symptoms but are more costly, may have assay-specific limitations (preferential amplification, reduced sensitivity for some targets), and are not validated for asymptomatic screening.
    Multiplex PCR / Respiratory panel — lab assay definition for multiple pathogens
    TermMultiplex PCR / Respiratory panel
    DefinitionA nucleic acid amplification-based laboratory assay that simultaneously detects and differentiates multiple respiratory pathogens (e.g., BioFire RP2.1, QIAstat-Dx, ePlex) from a single nasopharyngeal specimen.
    LimitationsDoes not provide quantitative values; not established for asymptomatic individuals and may require retesting if multiple organisms detected; negative result does not exclude infection.
    RT-LAMP — definition of reverse transcription loop-mediated isothermal amplification
    TermRT-LAMP
    DefinitionReverse transcription loop-mediated isothermal amplification — a rapid NAAT method operating at a single temperature using multiple primers and strand-displacing polymerase to amplify viral RNA without thermal cycling; can yield faster, instrument-sparing, sometimes colorimetric results.
    Potential useIntended to combine speed of antigen tests with greater accuracy of NAATs; several RT-LAMP and RT-LAMP–CRISPR platforms have been evaluated for SARS-CoV-2 detection.
    NGS / WGS — next-generation sequencing and whole genome sequencing definitions
    TermNGS / WGS (next-generation sequencing / whole genome sequencing)
    DefinitionHigh-throughput sequencing methods (NGS) and whole genome sequencing (WGS) used to generate sequence data for SARS-CoV-2 to support detection, gene-targeted assays, variant identification, and genomic surveillance.
    ApplicationsUseful for outbreak investigation, surveillance, and identifying introductions or variant circulation; requires specialized workflows for library prep, sequencing, and analysis; regulatory status and resource needs may limit routine clinical use.
    Whole genome sequencing (WGS) — description and uses
    TermWhole genome sequencing (WGS)
    DescriptionA sequencing process involving DNA/RNA fragmentation, bar-coding, high-throughput sequencing, and bioinformatic analysis to compare viral genomes for surveillance, outbreak investigation, and variant tracking.
    LimitationsWhile valuable for public health and surveillance, WGS lacks FDA-approved commercial tests for routine clinical use as of referenced updates and can be limited by cost, reagent availability, and infrastructure needs.
    SalivaDirect — EUA-authorized saliva-based RT-PCR test definition
    TermSalivaDirect
    DefinitionAn EUA-authorized saliva-based RT-PCR test developed by Yale School of Public Health that detects SARS-CoV-2 nucleic acids without requiring specialized extraction equipment; reported positive agreement 94.1% vs. TaqPath in EUA performance data.
    ConsiderationWHO does not recommend saliva as the sole specimen type for routine diagnostics, though SalivaDirect is an authorized saliva RT-PCR method with demonstrated agreement in evaluations.
    Ag-RDT — antigen-detecting rapid diagnostic tests and WHO performance thresholds
    TermAg-RDT (antigen-detecting rapid diagnostic test)
    WHO performance thresholdsMinimum performance recommended: ≥80% sensitivity and ≥97% specificity compared to a NAAT reference assay; recommended use within 5–7 days of symptom onset for symptomatic individuals.
    Intended useUseful for rapid diagnosis in settings with ongoing community transmission; results may be used for self-testing or point-of-care testing when users are trained and messaging is clear.
    Post-exertional malaise (PEM) — definition and typical timing
    TermPost-exertional malaise (PEM)
    DefinitionWorsening of symptoms following even minor physical or mental exertion, typically with symptom worsening 12 to 48 hours after activity and lasting days to weeks; commonly reported in Long COVID syndromes.
    Clinical contextOne of many Long COVID manifestations; objective testing cannot definitively diagnose Long COVID but PEM is a frequent symptom to assess clinically.
    Known exposure — definition of close contact and examples
    TermKnown exposure (close contact)
    DefinitionClose contact defined as at least 15 minutes within a 24-hour period with someone who has laboratory-confirmed COVID-19; suspected exposures include working or residing in congregate settings experiencing an outbreak.
    Testing implicationIDSA suggests testing asymptomatic exposed individuals at least 5 days after exposure or immediately if symptoms develop earlier.
    Antibody test utility — antibody tests indicate past infection or vaccination but cannot determine current infectiousness/time
    FactAntibody tests primarily indicate past infection or vaccination but cannot determine current infectiousness or time of infection.
    LimitationsSerology cannot be used to determine individual protective immunity or to make return-to-work, cohorting, or PPE decisions; spike-targeting assays cannot reliably distinguish vaccination from prior infection.
    Appropriate usesEpidemiology/seroprevalence, MIS-C evaluation (with NAAT), convalescent plasma donor screening, and vaccine-response studies when timed appropriately.
    MIS-C case definition (CSTE/CDC) — clinical and lab criteria reproduced
    TermMIS-C case definition (CSTE/CDC)
    Core criteriaIndividual <21 years with subjective or documented fever, clinical severity requiring hospitalization or death, CRP >3.0 mg/dL, new onset manifestations in ≥2 organ categories (cardiac, shock, mucocutaneous, gastrointestinal, hematologic), and detection of SARS-CoV-2 nucleic acid/antigen within 60 days or antibody associated with current illness or close contact within 60 days.
    Testing noteFor MIS-C evaluation, perform RT-PCR and serologic testing and send serology prior to IVIG administration.
    Antigen tests — referenced WHO and evaluations of antigen test performance
    TopicAntigen tests — referenced performance and evaluations
    ReferencesWHO Ag-RDT guidance and multiple evaluation studies and FDA EUA summaries are cited supporting thresholds and timing for antigen test use.
    Practical implicationUse Ag-RDTs where recommended performance met; negative antigen results in symptomatic patients should be confirmed with molecular NAAT when clinically required.
    Genomic/NGS testing — methods and EUA summaries for genomic testing
    TopicGenomic/NGS testing — methods and EUA summaries
    MethodsNGS workflows include library preparation, sequencing of bar-coded fragments, and bioinformatic comparison to reference genomes; applicable EUAs (e.g., Illumina COVIDSeq, Helix COVID-19 NGS) have been issued for SARS-CoV-2 applications.
    Use cases & limitsValuable for surveillance, outbreak investigation, and variant detection; constrained by regulatory status, cost, and infrastructure requirements for routine clinical implementation.